These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Search MEDLINE/PubMed
Title: Prospective Study of Pathogenesis of Atrophic Acne Scars and Role of Macular Erythema. Author: Tan J, Bourdès V, Bissonnette R, Petit B Eng L, Reynier P, Khammari A, Dreno B. Journal: J Drugs Dermatol; 2017 Jun 01; 16(6):566-572. PubMed ID: 28686774. Abstract: <p>BACKGROUND: There are few studies on the natural history of acne lesions including the antecedents of atrophic scars.</p> <p>STUDY DESIGN: Prospective study of relationship between primary (papules, pustules, comedones) and secondary lesions (atrophic scars, macular erythema, and hyperpigmentation) over 6 months. Subjects (n=32) had moderate facial acne including 10 or more atrophic acne scars and were their own control via randomized split-face design. Lesions were mapped 2x/week for 2 months and every 2 weeks thereafter until month 6 to track pathogenic progression.</p> <p>RESULTS: Clinical assessment showed acne scars continuously forming throughout the 6-month study period. While the majority (66.2%) of these scars did not resolve by study endpoint, the remainder were transient. The likelihood of a scar developing from a primary acne lesion was 5.7%, and almost all scars arose from erythematous macules or hyperpigmentation (83%) and some (16%) developed directly from papules and pustules. Duration of papules was a key factor in the risk of scarring. The majority (81.7%) of the scars remaining at 6 months were still present at 2-year follow-up.</p> <p>CONCLUSIONS: Atrophic acne scars continuously form, some resolve, and evolve primarily from inflammatory and post-inflammatory lesions. Clinicians should closely monitor patients with macular erythema for scarring.</p> <p><em>J Drugs Dermatol. 2017;16(6):566-572.</em></p>.[Abstract] [Full Text] [Related] [New Search]